Status:
RECRUITING
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
Lead Sponsor:
Gene Solutions
Conditions:
Rectal Cancer
Rectal Cancer Stage II
Eligibility:
All Genders
18-80 years
Brief Summary
This is a prospective observational study with three primary objectives: Objective 1: Evaluate the detection rate and changes in circulating tumor DNA (ctDNA) levels in blood samples from colorectal ...
Detailed Description
This is a prospective observational study conducted at the Medical Genetics Institute (MGI), in collaboration with 3 hospitals (175 Military Hospital, Nguyen Tri Phuong Hospital, and 108 Military Cent...
Eligibility Criteria
Inclusion
- 18 years and older, both genders
- Patients are diagnosed with stage II-III rectal cancer and indicated for total neoadjuvant therapy
- Biopsy FFPE sample is available at the time of diagnosis
- Patients consented to participate in the study
Exclusion
- Stage I rectal cancer, recurrent or metastatic cancer
- Other cancer metastasis to the rectum
- Patients are indicated for chemoradiation therapy only
- Have been or are being treated for cancer
- Patients do not agree to participate in the studies.
Key Trial Info
Start Date :
May 21 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06589388
Start Date
May 21 2024
End Date
December 1 2027
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Genetics Institute
Ho Chi Minh City, Vietnam